X

Trial Profile

An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs M 8891 (Primary)
Indications Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors EMD Serono Research & Development Institute

Most Recent Events

29 Oct 2020 Status changed from recruiting to active, no longer recruiting.
21 Sep 2020 Preliminary results (n=24) of dose escalation part of this trial presented at the 45th European Society for Medical Oncology Congress
15 Jul 2020 Planned number of patients changed from 27 to 97.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com